Indication
Uterine Corpus Leiomyosarcoma AJCC v8
3 clinical trials
4 products
1 drug
Clinical trial
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue SarcomasStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
CabozantinibProduct
TMZClinical trial
A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior ChemotherapyStatus: , Estimated PCD: 2030-03-09
Product
OlaparibProduct
PazopanibDrug
TrabectedinClinical trial
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine LeiomyosarcomaStatus: Active (not recruiting), Estimated PCD: 2020-08-01